Panacea Biotec enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


2,017	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
67.3	67.3	85.3	87.5	53.3
−6.0	−6.0	−4.2	−3.8	−3.5
23.7	23.7	22.2	21.0	20.2
1,967	—	—	—	—
−43.7	−43.7	−63.1	−66.5	−33.1
₹320.95	—	—	—	—

853	853	853	859	860
2.8%	2.8%	2.6%	2.4%	2.4%
0.01×	—	—	—	—

2.92×	—	—	—	—
898.37×	—	—	—	—
−64.76×	—	—	—	—
673	640	559	559	460
2.2	−4.7	−25.9	−20.1	−98.0
−30.4	−37.7	−60.7	−56.8	−137
—	16.7	−27.4	−0.1	−423
−37.4	−37.4	−77.7	−77.8	−464
—	−37.5	−77.7	−79.4	−467
—	54.1	50.3	77.7	41.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

PANACEABIO₹329.05

Panacea Biotec Limited

· Pharma & Health

₹ CrorePeersSAIPARENT HIKAL INDOCO DCAL WINDLAS HESTERBIO SOLARA SYNCOMFMcap ₹2,017 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	2,017.1
- Cash, Equiv & ST Investments	53.3	87.5	85.3	67.3	67.3
+ Minority Interest	-3.5	-3.8	-4.2	-6.0	-6.0
+ Total Debt	20.2	21.0	22.2	23.7	23.7
Enterprise Value	—	—	—	—	1,967.4
Net Debt (memo)	-33.1	-66.5	-63.1	-43.7	-43.7
EV per Share	—	—	—	—	320.95

Total Capital	860.3	859.2	852.8	852.5	852.5
Total Debt/Total Capital	2.35	2.44	2.60	2.78	2.78
Total Debt/EV	—	—	—	—	0.01

EV/Sales	—	—	—	—	2.92
EV/EBITDA	—	—	—	—	898.37
EV/EBIT	—	—	—	—	-64.76
Reference Items — Trailing FY Values
Sales	460.0	559.2	559.1	639.8	672.6
EBITDA	-98.0	-20.1	-25.9	-4.7	2.2
EBIT	-137.1	-56.8	-60.7	-37.7	-30.4
Operating Cash Flow	-423.5	-0.1	-27.4	16.7	—
Free Cash Flow	-464.4	-77.8	-77.7	-37.4	-37.4
FCFF (free cash flow to the firm)	-466.6	-79.4	-77.7	-37.5	—
Capital Expenditure	41.0	77.7	50.3	54.1	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.